To include your compound in the COVID-19 Resource Center, submit it here.

Aug. 19 Clinical Quick Takes: Kalytera's cannabidiol shows promise for transplant, plus Abbisko and Brigham and Women's

Kalytera's CBD prevents graft-vs-host disease
Kalytera Therapeutics Inc. (TSX-V:KLY; OTCQB:KALTF) announced plans to start a Phase III registrational trial of cannabidiol after low and medium doses

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers